期刊文献+

联合检测血清HE4和CA125对卵巢恶性肿瘤的诊断价值 被引量:11

Diagnostic value of serum HE4 combined with CA125 detected for ovarian malignant tumor
原文传递
导出
摘要 目的探讨血清中人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原-125(carbohydrate antigen 125,CA125)对卵巢恶性肿瘤的诊断价值。方法测定123例女性血清标本,其中卵巢恶性肿瘤34例,卵巢良性疾病39例,健康体检女性50例,用酶联免疫分析法(enzyme-linked immunosorbentassay,ELISA)和电化学发光法(electrochemiluminescence immunoassay,ECLIA)分别检测血清HE4和CA125水平。结果卵巢恶性肿瘤组血清HE4和CA125水平明显高于其他两组,差异有统计学意义(P<0.05);卵巢良性疾病组和健康对照组HE4比较差异无统计学意义(P>0.05)。以卵巢良性疾病作参照,单独检测血清HE4水平对卵巢恶性肿瘤诊断的敏感性为61.8%,低于单独检测CA125的73.5%;但特异性96.6%,高于CA125的80.9%。以二者其中之一高于参考值即视为阳性,联合检测血清HE4和CA125水平对卵巢恶性肿瘤诊断的敏感性94.1%,特异性80.9%,阴性预测值97.3%。结论检测血清HE4和CA125水平可明显提高卵巢恶性肿瘤诊断的准确率,并有助于卵巢良、恶性疾病的鉴别诊断。 Objective To study the diagnostic value of serum human epididymis protein 4(HE4) combined with carbohydrate antigen 125(CA125) detected for ovarian malignant tumors.Methods Serum samples of HE4 and CA125 levels from 123 cases including 34 cases with ovarian malignant tumors(in ovarian malignant tumors group),39 cases with benign ovarian diseases(in ovarian benign diseases group) and 50 healthy women(in control group) were detected by enzyme-linked immunosorbent assay(ELISA) and electrochemiluminescence immunoassay(ECLIA).Results Serum HE4 and CA125 levels in ovarian malignant tumors group were significantly higher than that in the other two groups and the difference was statistically significant(P0.05).Serum HE4 between benign disease group and control group was no significant difference(P0.05).Reference to benign ovarian diseases,diagnostic sensitivity of HE4 levels(61.8%) single detected for ovarian malignant tumors was lower than that of CA125(73.5%) alone detected.But the specificity of HE4 levels(96.6%) in ovarian malignant tumors was higher than that of CA125(80.9%) alone detected.Whichever one higher than the reference value was as positive.Diagnostic sensitivity,the specificity and negative predictive value of HE4 and CA125 combined detection was 94.1%,80.9%,of 97.3% respectively.Conclusion HE4 and CA125 combined detection can improve the diagnostic accuracy for ovarian malignant tumors and conduce to differential diagnosis for ovarian benign and malignant diseases.
作者 徐萌 李慧源
出处 《中国计划生育和妇产科》 2011年第3期52-55,共4页 Chinese Journal of Family Planning & Gynecotokology
关键词 人附睾蛋白4 糖链抗原-125 卵巢恶性肿瘤 human epididymis protein 4(HE4) carbohydrate antigen 125(CA125) ovarian malignant tumors
  • 相关文献

参考文献8

  • 1丰有吉.妇产科学[M].第2版.北京:人民卫生出版社,2010:68-69.
  • 2Schummer M, Ng W V, Bumgamer RE, et al. Comparative hybridization of an array of 21500 ovarian cDNAs for the dis - covery of genes over expressed in ovarian carcinomas [ J ]. Gene,1999, 238:375 -385.
  • 3Wang K, Gan L, Jeffrey E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray [ J ]. Gene, 1999, 229:101 -108.
  • 4Hellstrom I, Raycraft J, Schummer M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res, 2003, 63 : 3695 - 3700.
  • 5董丽,昌晓红,叶雪,朱丽荣,赵旸,田莉,程洪艳,李小平,张虹,廖秦平,付天云,成夜霞,崔恒.血清人附睾分泌蛋白4和CA125水平检测在卵巢恶性肿瘤中的诊断价值[J].中华妇产科杂志,2008,43(12):931-936. 被引量:98
  • 6Drapkin R, Lin Y, Mok SC, et al. Human an epididym is prote in 4(HEA) is a secreted glycoprote in that is over expressed by serous and endomertrioid ovarian carcinomas [ J ]. Cancer Res, 2005, 65: 2162 - 2169.
  • 7Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues [ J ]. Modem Pathology, 2006, 19:847-853.
  • 8Bouchand D, Morisset D, Bourbonnais Y, et al. Proteins with wheyacid- prote in motifs and cancer[ J]. Lancet Oncol, 2006, 7 (2) : 167 -174.

二级参考文献8

  • 1Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother,2004,58 : 24 -38.
  • 2Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer,2000,82 : 1535-1538.
  • 3Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63 : 3695 -3700.
  • 4Israeli O, Goldring-Aviram A, Rienstein S, et al. In sihco chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet,2005 ,160 :35- 42.
  • 5Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 ( HE4 ) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169.
  • 6Kirchhoff C, Habben I, Ivell R, et al. A major human epididymisspecific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 1991,45: 350- 357.
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108:402-408.
  • 8刘润幸.使用SPSS作多变量观察值的ROC曲线分析[J].中国公共卫生,2003,19(9):1151-1152. 被引量:128

共引文献301

同被引文献115

  • 1DAN-HUI LIU,XIAO-MIN WANG,LI-JUAN ZHANG,SONG-WEI DAI,LI-YUN LIU,JI-FU LIU,SHAN-SHAN WU,SHUAN-YING YANG,SAM FU,XUE-YUAN XIAO,DA-CHENG HE.Serum Amyloid A Protein: A Potential Biomarker Correlated With Clinical Stage of Lung Cancer[J].Biomedical and Environmental Sciences,2007,20(1):33-40. 被引量:12
  • 2杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量:17
  • 3乐杰.妇产科学[M].北京:人民卫生出版社,2003.360.
  • 4Goonewardene TI, Hall MR, Rustin GJ. Management of asymptornatic patients on follow-up for ovarian cancer with rising CA-125 coneentra- tions[J]. Lancet Oncol, 2007,8 (9) : 813-821.
  • 5Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive a- nalysis of HE4 expression in normal and malignant human tis- sues[J]. ModPathol,2006,1(19):847 853.
  • 6Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma sub-types are different disease implications for biomarker studies [J]. Plos Med,2008,5(12) :232.
  • 7Bandiera E, Ragnoli M, Zanotti L. Clinical role of human epididy- mis protein 4 (HE4) in epithelial ovarian cancer[J]. Oncol, 2009,1(3) : 143.
  • 8Ailard J,Somers E,Theil R,et al. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer[J]. Cln On col,2008,26(15) :5535.
  • 9Anderson GL,McIntoshMW. Assessing lead time of selected o varian cancer biomarkers:a nested case-control study[J]. JNCI, 2010,102(1):438.
  • 10Bast Jr RC.Status of tumour markers in ovarian cancer screening[J].J Clin Oncol,2003,21(Suppl 10):200-205.

引证文献11

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部